GSOR02   Presentation Time: 12:05 PM
Brachytherapy (BT) target dose and coverage are critical to the cure of locally advanced cervical cancer (CC). Advances in imaging, volumetric definitions, and BT planning aims/constraints have collectively been associated with improved tumor control outcomes over traditional practices. But some historic conventions remain in BT, such as applying uniform radiobiological parameters (RbP). Having previously generated a/b and T1/2 from CC cell lines, we explored the potential impact of differing RbP against population-based outcomes in an era of MR-BT boost. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Fleur Huang, Sunita Ghosh, Shyam Menon, Braden Chow, Julie Cuartero, Armin Gamper, Brad Warkentin, Ericka Wiebe, Corinne Doll, Geetha Menon Source Type: research

GSOR03   Presentation Time: 12:10 PM
To report procedure time for novel MRI catheter tracking technology in patients undergoing template-based interstitial gynecologic brachytherapy implants. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Michael Roumeliotis, Majd Antaki, Junghoon Lee, Khadija Sheikh, Ehud Schmidt, Akila Viswanathan Source Type: research

GSOR04   Presentation Time: 12:15 PM
MRI-based brachytherapy for cervical cancer results in superior soft tissue delineation and unprecedented local control and toxicity rates. The vast majority of outcomes data are reported from European populations. Our institution initiated an MRI-based brachytherapy program in 2014, and this study updates our outcomes and toxicities at a U.S. academic center. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Dylan Ross, Kayeromi Gomez, Grant Harmon, Michael Mysz, Steven Shea, Ari Goldberg, Margaret Liotta, Ronald Potkul, Abigail Winder, Brian Lee, John Roeske, William Small, Matthew Harkenrider Source Type: research

GSOR05   Presentation Time: 12:20 PM
Image-guided brachytherapy (IGBT) with MRI for locally advanced cervical cancer (LACC) has significantly improved our ability to define gross tumor and adapt radiation treatment accordingly. High local control and low toxicity with MRI-IGBT for brachytherapy (BT) have been demonstrated in recent series. Dose-effect relationships for the volume (in cc) of residual gross tumor (GTV) at the time of brachytherapy is prognostic for clinical outcomes. The purpose of this study is to evaluate the percentage change in tumor volume at the time of IGBT and the dose-response relationship. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Emilee Hall, Bethany Horton, Ruyun Jin, Matthew Mistro, Bryant Walker, Kara Romano, Einsley-Marie Janowski Source Type: research

GSOR06   Presentation Time: 12:25 PM
Following the treatment of locally advanced cervical cancer (LACC) with chemoradiation (CRT) and brachytherapy (BT), the evaluation of treatment response using positron-emission tomography (PET) is commonly used. It is unclear, however, whether indeterminate or equivocal PET response at 3 months on radiologist reading within the high risk clinical target volume (HRCTV) correlates to ongoing treatment response versus persistent disease. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Rachel F. Shenker, Jessica Lee, Sarah Jo Stephens, Diandra Ayala-Peacock, Junzo Chino Source Type: research

GSOR07   Presentation Time: 12:30 PM
This study sought to evaluate potential of two direction modulated brachytherapy (DMBT) tandem applicators combined with one DMBT ovoids of unique designs to effectively removing the need for IS needles in a range of IC-IS cases found in multi-institutional clinics via achieving equivalent or better dosimetry. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Sharmin Alam, Dylan Richeson, Binod Manandhar, Somayeh Gholami, Suman Gautam, Daniel Scanderbeg, Catheryn M. Yashar, Joann Prisciandaro, Shruti Jolly, Emma Fields, William Y. Song Source Type: research

GSOR08   Presentation Time: 12:35 PM
We report our experience with interstitial brachytherapy, outcomes, and dose volume histogram (DVH) metrics. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Aranee Packiam Sivananthan, Connor Lynch, Tianming Wu, Hania Al-Hallaq, Christina H. Son, Yasmin Hasan Source Type: research

GSOR09   Presentation Time: 12:40 PM
Management of gynecologic brachytherapy(BT) procedural pain or discomfort varies across institutions. Data suggest women experience symptoms of acute stress disorder and post-traumatic stress disorder (PTSD), as high as 30-41%, following BT with spinal/epidural anesthesia (AS)1. We sought to determine the prevalence of post-BT PTSD in our locally advanced cervical cancer (LACC) patients and differences based on the type of AS. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Amanda Rivera, Monica Wassell, Deepthisri Suresh, Sarah McNeilly, Shankar Viswanathan, Nitin Ohri, Shalom Kalnicki, Ravindra Yaparpalvi, Irene Osborn, Justin Tang, Keyur J. Mehta Source Type: research

GSOR10   Presentation Time: 12:45 PM
To describe the experiences of cervical cancer patients regarding education about and preparedness for brachytherapy (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Onyinye Diane Balogun, Eve McDavid Source Type: research

GSOR11   Presentation Time: 12:50 PM
Endometrial cancer (EC) is the fourth most prevalent malignancy in females, and the leading gynecologic cancer [1]. Although the incidence of EC is 33% lower in Black women, they are 41% more likely to present with advanced stage disease and have an 80% higher mortality [2, 3]. Standard of care for EC includes total vaginal hysterectomy +/- adjuvant chemotherapy or radiation therapy (RT) [4]. These treatments are associated with side effects such as vaginal stenosis or shortening, which could be improved with vaginal dilator use [4]. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Shubhangi Shah, Xiaoyan Deng, Emma Fields, Dipankar Bandyopadhyay, Bridget D. Quinn Source Type: research

GSOR12   Presentation Time: 12:55 PM
Uterine cancer remains the most commonly diagnosed gynecologic malignancy. Surgical resection is the mainstay of treatment and is followed by risk-adapted adjuvant therapy. Although randomized data exists comparing brachytherapy +/- EBRT, there is no high-level evidence guiding the use of VCB after EBRT. Retrospective data supports VCB following EBRT for locally advanced uterine cancers in the presence of cervical stromal invasion (+CSI) and/or positive margins (+SM). Lymphovascular space invasion (LVSI) predicts for lymph node involvement and cancer recurrence, but its status as an independent risk factor associated with ...
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Cristina DeCesaris, Christopher Weil, Jessica Cruttenden, Lindsay Burt, Gita Suneja, David Gaffney Source Type: research

GYN Posters PO01
The use of brachytherapy in the treatment of cervical cancer in the United States (USA) (stage IIB-IVA) has declined even though brachytherapy (BT) is associated with improved overall survival. Two main reasons are lower reimbursement for BT compared to external beam radiation therapy (EBRT) and the high cost of providing brachytherapy. Optimizing the BT workflow could reduce time and treatment costs and potentially increase its use. One way to improve efficiency in the workflow is the use of a one-room brachytherapy suite with CT (ORBT). (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Evelien van Well, Tim Govers, Stavroula Giannouli, Elena Nioutsikou, Bob Hamans, Maroeska Rovers, Timothy Showalter Source Type: research

Po02
Definitive radiotherapy (RT) for locally advanced cervical cancer in the US includes external beam radiotherapy (EBRT) with brachytherapy (BT). Although there are ABS guidelines for BT dose/fractionation regimens, there is limited data on actual usage. Our project aims to provide a contemporary assessment of cervical cancer BT boost modality and dose/fractionation regimens in the US, and their associations with patient/facility characteristics and impact by COVID-19 pandemic. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Kristin Hsieh, Celina Hsieh, Julie R. Bloom, Jagdeep Raince, Vishal Gupta Source Type: research

Po03
We report our initial experience with the Getinge Pilot System, initially designed for neurosurgery, after it was modified to be used in a brachytherapy suite. The objective was to develop a workflow integrating Magnetic Resonance Imaging (MRI) and standard Computed Tomography (CT) for each GYN brachytherapy fraction without compromising patient access and minimizing motion. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Martine LeFebvre, William Foster, Eric Vigneault, Marie-Anne Froment, Luc Beaulieu, Eric Poulin, Frederic Lacroix, Nathalie Dufour Source Type: research

Po04
The conventional vaginal cylinder design consists of cylindrical segments and a hemi-spherical top, with a diameter matched to the cylinder portion. This design is driven primarily by geometric simplicity, without much consideration for the dose distribution around the brachytherapy source, nor the anatomy of patients. Careful plan optimization is required to make the prescription isodose line conform to the surface of the cylinder. However, the conformity is not optimal due to the discrepancy between the cylinder shape and the intrinsic dose anisotropy of the source perpendicular to the azimuthal plane. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Yixiang Liao, Ken Tatebe, Julius Turian Source Type: research